Core Viewpoint - Dexcom experienced a challenging year in 2024, with shares down 19% over the trailing-12-month period, but there are compelling reasons to consider investing in the company [1] Group 1: Challenges Faced - Dexcom faced regulatory scrutiny and customer complaints due to defects in some continuous glucose monitoring (CGM) receivers, leading to a Class 1 recall of 602,445 G7 receivers [2] - The recall was precautionary, and many patients opted to use a mobile app instead of the receiver, indicating that demand for Dexcom's products remains strong despite the issues [3] Group 2: Financial Performance - In Q3 2024, Dexcom's revenue grew by 22% year over year to $1.2 billion, with adjusted earnings per share increasing by 35.6% to $0.61 compared to the previous year [4] - The company ended 2024 with approximately 2.8 million to 2.9 million customers, a number likely to have increased in 2025, with only 112 complaints received regarding the defective receivers [4] Group 3: Growth Potential - Dexcom is a leader in the CGM market and has significant growth opportunities, particularly among patients with type 1 diabetes and those with type 2 diabetes on intensive insulin therapy, which have historically been the primary target markets [5] - There remains a large addressable market within the core U.S. market, indicating potential for further expansion [5]